renegade.bio and CASPR Biotech have announced a strategic collaboration on cost-effective and highly precise diagnostics for the detection of SARS-CoV-2. The R+D partnership will combine both companies’ expertise in molecular biology, bioinformatics, and engineering to expedite the development and commercialization of a CRISPR-based rapid CLIA-waived test.
renegade.bio and CASPR Biotech are both alumni of the IndieBio accelerator and represent a select group of SOSV investees focused on the 2020 global pandemic.
Formed in March 2020, renegade.bio is dedicated to collaborating across the ecosystem of public health to make coronavirus testing accessible to all, regardless of income. “By facilitating the development of point-of-care assays such as the CASPR assay, we offer the community a fast and effective way to determine their status in real-time. It is a great opportunity to relieve the burden of the novel coronavirus pandemic,” said Craig Rouskey, renegade.bio CEO.
CASPR Biotech, founded in Argentina in early 2019, uses CRISPR technology, together with bioinformatics and genomics technology, to develop rapid patient-centric diagnostic solutions that enable health professionals to make time-critical decisions at the point of care. “We are delighted to leverage renegade.bio’s expertise in high complexity testing. It is vital in enabling us to optimize our rapid test, validating our kits for patient use,” commented Franco Gyoti, CASPR Biotech CEO.
As a Queer owned and operated public benefit corporation, renegade.bio is accelerating humanity’s capacity to test for novel pathogens such as COVID-19. The company empowers an overburdened public health system to respond swiftly to epidemiologic crises by delivering fast, reliable, cost-effective solutions for community-based triage.
In collaboration with other laboratories, researchers, and organizations across the ecosystem of public health, renegade.bio is working day and night with a singular goal to make COVID-19 testing accessible to everyone regardless of income.
For more information, see www.renegade.bio.
Caspr Biotech is developing rapid-portable molecular diagnostics solutions based on novel CRISPR Cas enzymes. The company has recently submitted for FDA EUA the Caspr Lyo-CRISPR SARS-CoV-2 Kit, a solution that is set to enable professionals to perform COVID-19 diagnostics in less than 60 minutes, with minimal requirements in terms of external equipment.
For more information visit: https://caspr.bio
renegade.bio
Craig Rouskey, CEO
(510) 407-6775
craig@renegade.bio
CASPR Biotech
Anselmo Reggiardo, Director of Sales
(415) 212-6560
anselmo@caspr.bio
